Increased Infection Rate After Preemptive Rituximab Treatment for Epstein-Barr Virus Reactivation After Allogeneic Hematopoietic Stem-Cell Transplantation

Authors :: Petropoulou, Anna D.
Porcher, Raphael
Latour, Regis Peffault de
Xhaard, Alienor
Weisdorf, Daniel
Ribaud, Patricia
Rodriguez-Otero, Paula
Agbalika, Félix
Talbot, Alexis
Toubert, Antoine
Moins-Teisserenc, Hélène
Carmagnat, Maryvonnick
Socié, Gerard
Robin, Marie
Source :: Transplantation; October 2012, Vol. 94 Issue: 8 p879-883, 5p
Publication Year :: 2012
Abstract: Preemptive rituximab (R) treatment decreases the incidence of Epstein-Barr virus (EBV) posttransplantation lymphoproliferative disease, but the extent of immune deficiency related to R in patients who received allogeneic hematopoietic stem-cell transplantation is unclear. The aim of our study was to evaluate the incidence of late infections and immune reconstitution after preemptive R treatment of EBV infection.

Full Text Access

Tools